Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313730 | 0.80 | GRM5 (0.47) | GRM5PTPN11PTPN1 | |
| SCHEMBL6315557 | 0.80 | PTPN11 (0.43) | GRM5PTPN11PTPN1 | |
| SCHEMBL9302636 | 0.78 | CA12 (0.62) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL31286312 | 0.78 | CA12 (0.62) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL9304700 | 0.74 | CA12 (0.62) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL2728344 | 0.73 | PTPN11 (0.54) | PTPN11PTPN1 | |
| SCHEMBL6793023 | 0.72 | GRM5 (0.56) | GRM5 | |
| SCHEMBL717450 | 0.72 | CA12 (0.59) | GRM5CA12CA2CA9CA1 | |
| SCHEMBL6786957 | 0.70 | PTPN11 (0.42) | PTPN11PTPN1 | |
| SCHEMBL6322289 | 0.70 | GRM5 (0.44) | GRM5CA12CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014938-A1 | Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase | GASTER LARAMIE MARY (GB) | 2005-01-20 | — | — | US | disclosed |
| EP-1444232-A1 | PHENYL SUBSTITUTED TRIAZOLES AND THEIR USE AS SELECTIVE INHIBORS OF AKL5 KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003042211-A1 | PHENYL SUBSTITUTED TRIAZOLES AND THEIR USE AS SELECTIVE INHIBORS OF AKL5 KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014938-A1 | Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase | AKR1C3, CBR3, PHKG1 | GRM5 1589/4885CA12 3702/4885CA2 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.